Enumeral names Wael Fayad as chairman, president, and CEO
Mr. Fayad brings to Enumeral more than two decades of senior executive and business development experience in the life sciences industry.
From 2001 to 2014, Mr. Fayad held positions of increasing responsibility at Forest Laboratories, Inc., most recently as Corporate Vice President, Global Business Development.
He helped build and manage a broad network of partnerships at Forest, and upon Forest’s acquisition by Actavis, Mr. Fayad also assisted with the integration of the two companies.
Mr. Fayad was subsequently engaged in a number of entrepreneurial ventures, including helping to launch V&C Pharmaceuticals, a start-up company. Mr. Fayad continues to serve on V&C Pharmaceuticals’ advisory board.
Prior to Forest, Mr. Fayad served in positions of increasing responsibility at Schering-Plough and Novartis in the fields of sales, marketing, and new product development.
Mr. Fayad holds a B.S. in biology from the American University of Beirut, and an M.B.A. from Concordia University.
In connection with Mr. Fayad’s appointment as Chairman, President, and Chief Executive Officer, John J. Rydzewski stepped down as Enumeral’s Executive Chairman and from the Company’s Board of Directors.
Arthur H. Tinkelenberg, Ph.D., Enumeral’s former President and Chief Executive Officer, also stepped down from the Company’s Board of Directors. ■
LATEST MOVES FROM Massachusetts
- DentaQuest appoints Alison Corcoran as CMO
- RXI Pharma names Gerrit Dispersyn chief development officer
- resTORbio appoints Joan Mannick as CMO
- C&W Services appoints Mike Losier as director
- Charles River Associates appoints Robert A. Whitman to board
More inside POST